Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

7Total
P 2 (7)

Trial Status

Recruiting5
Not Yet Recruiting1
Unknown1

Clinical Trials (7)

Showing 7 of 7 trials
NCT07233252Phase 2Recruiting

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

NCT04138719Phase 2Recruiting

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

NCT04159142Phase 2Recruiting

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

NCT07126119Phase 2Recruiting

Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC

NCT07125547Phase 2Recruiting

Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

NCT07089199Phase 2Not Yet Recruiting

Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer(TitAN) : A Prospective, Single-Arm, Phase II Study

NCT03779464Phase 2Unknown

Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas

Showing all 7 trials

Research Network

Activity Timeline